Summary of Biotechnology Trends: Moderna is being sold off in a "positive cash in" manner, as AI giants continue to expand into life sciences BlockBeats reported that on October 23rd, Moderna experienced a sell-off due to the early disclosure of data from the personalized cancer vaccine phase III trial. According to BIT (bit. com) market data, on October 22nd, its stock price closed down 17.57% at $202.63, hitting a intraday low of $180.80, down about 26.45% from the previous closing price. On August 19th, news of positive results from related experiments had pushed its stock price up 177% in a single day. It is worth noting that this disclosure is not a failure of the experiment. Merck and Moderna subsequently announced that in the INTerpath-001 Phase III trial, personalized therapy Intiseman combined with Keytruda reduced the risk of recurrence or death in specific postoperative melanoma patients by 42% and the risk of distant metastasis or death by 38% compared to using Keytruda alone. The overall survival data is not yet mature, and research is still ongoing. Analysts believe that the decline in stock prices is a reaction to the "sell news" after the previous continuous rise. In addition, AI giants are still continuously expanding their life science business. OpenAI announced on October 20th the acquisition of Orchestra Bio, a company that develops an AI platform to help biopharmaceutical teams coordinate drug development. The team and technology will be integrated with OpenAI's life science tool Rosalind, and the transaction amount has not been disclosed. OpenAI also stated that it has collaborated with Moderna and Novo Nordisk to utilize AI in their research and development processes. Anthropic previously acquired AI biotech company Coefficient Bio, with a reported transaction amount of approximately $400 million, to be paid in stock. Anthropic has started internal biological laboratory work, and the head of its life science business stated that life science has become one of the company's largest investment areas in terms of personnel and resource investment. Nvidia announced on October 21st that it has partnered with the Protein Design Institute at the University of Washington to launch the open model RFD4 Prototina for protein design and search. Benchling, Boltz, Danaher, Automata, and other companies are also using their BioNeMo platform to develop scientific AI agents that connect drug design, biological data, and automated laboratory workflows. In terms of mergers and acquisitions of large pharmaceutical companies, according to the company's announcement on October 19th, Merck KGaA of Germany has signed an agreement to acquire RNA interference therapy developer Silence Therapeutics for $20 per American depositary share in cash, a premium of 130% over its closing price on October 16th. The transaction corresponds to an equity value of approximately 1.3 billion US dollars and is expected to be completed in the first quarter of 2027. Approval from shareholders, courts, and regulators is still required. Merck in Germany and Moderna's partner Merck in the United States are different companies.